Cardiology
Commentary
TAVR quickly penetrates to low-risk patients
Conference Coverage
Defibrillation testing at ICD placement did not reduce failed shocks or arrhythmic deaths
Key clinical point: Routine defibrillator testing may be unnecessary at placement of an implanted cardioverter defibrillator.Major finding: Failed...
News
Remote monitoring of devices boosted survival
Key clinical point: Survival was higher when patients with pacemakers and defibrillators participated in remote monitoring programs.Major finding...
Conference Coverage
Empagliflozin improves glycemia, blood pressure in type 2 diabetes study
Key clinical point: A treatment approach that includes control of blood pressure and hyperglycemia might reduce the risk of cardiovascular...
Conference Coverage
20-study analysis finds no MACE increase with saxagliptin
Major finding: The incidence of MACE composite endpoint was similar among patients treated with saxagliptin (0.85/100 person-years) and controls (...
Conference Coverage
No link seen between ondansetron and tachyarrhythmias in healthy children
Top clinical point: The study findings support cardiac monitoring for children with cardiac diagnoses who are receiving ondansetron.
News
Posaconazole disappoints against chronic Chagas’ disease
Major finding: The primary end point of the study, consistently negative results on serial T.
Conference Coverage
Six factors predict 1-year survival after TAVR
Key clinical point: One-year outcome data from almost 6,000 U.S.
News
UPDATED: FDA-released safety data on dabigatran vs. warfarin reassuring
Major finding: The risks of ischemic stroke, intracranial hemorrhage, and death associated with dabigatran treatment were lower than with warfarin...
News
Adding evolocumab to statins further lowered LDL cholesterol
Major finding: Of patients who received additive evolocumab, 86%-94% achieved LDL-cholesterol levels of less than 70 mg/dL, compared with only 17...
Conference Coverage
Apixaban for VTE reduced subsequent hospitalizations
Major finding: Patients whose acute venous thromboembolism was treated with 6 months of apixaban were 21% less likely to have another...